Steroid-induced diabetes mellitus is one of the highly frequent side effect of glucocorticoid agents, and is suggested to be due to insulin resistance. The new oral hypoglycemic agent pioglitazone, which improves insulin resistance, is being used clinically to treat diabetes mellitus.
We randomly classified 40 cases into two groups of 20 subjects each. Pioglitazone was administered to one group and not to the other. We conducted an oral glucose tolerance test (OGTT) on the two groups before and six months after the administration of pioglitazone, then examined changes in both plasma glucose and plasma immunoreactive insulin.
As a result, hemoglobin Aic (HbA
1c) decreased from 7.88±0.28% to 6.64±0.10%(mean±SE) six months after the administration of pioglitazone. Pioglitazone significantly decreased two-hour plasma glucose (291.7±13.36 mg/d
l to 203.0±8.93 mg/d
l, mean±SE), which revealed insulin resistance in skeletal muscle, and decreased HOMA-R (3.36±0.28% to 1.98±0.27, mean±SE), which revealed hepatic glucose production.
In conclusion, we showed that both control of plasma glucose and of insulin resistance were improved by administration of pioglitazone, which potentiates insulin action and reduces insulin resistance. Our results suggest that the administration of pioglitazone has positive clinical effects on steroid-induced diabetes mellitus.
View full abstract